A Novel Small‐Molecule Dual Adiponectin Receptor 1/2 Agonist Induces Myogenesis and Ameliorates Skeletal Muscle Atrophy
Journal of Cachexia, Sarcopenia and Muscle · 2026
DOI: 10.1002/jcsm.70364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Shubhrajyoti Das und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Receptors, Adiponectin, Muscular Atrophy, Muscle Development, Muscle, Skeletal. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Council of Scientific and Industrial Research, India, Blockchain for Impact-BIOME.
Abstract (Originalsprache)
Background
Skeletal muscle atrophy is a hallmark of ageing and chronic diseases, yet effective pharmacotherapies remain unavailable. Adiponectin signalling through AdipoR1 and AdipoR2 regulates skeletal muscle metabolism, regeneration and oxidative capacity, but the therapeutic use of adiponectin is limited by its large size and complex multimeric structure. Small‐molecule AdipoR agonists, therefore, represent an attractive therapeutic strategy.
Methods
A PGC‐1α promoter‐luciferase assay was used to screen for AdipoR agonists in HEK‐293T cells overexpressing AdipoR1 or AdipoR2. Receptor specificity was validated through receptor overexpression and RNA‐interference. C2C12 myoblast differentiation was assessed using phase‐contrast microscopy and myosin heavy chain (MyHC) immunostaining followed by morphometric analyses of cross‐sectional area (CSA) and Feret's diameter, along with immunoblotting of MyoD and myogenin. Anti‐atrophy effects were examined in myotubes exposed to dexamethasone, cytokines or nutrient deprivation by evaluating CSA and diameter through morphometry, immunoblotting and qRT‐PCR analysis of atrogenes and myogenic markers. Oxidative metabolism and mitochondrial function were analysed using extracellular flux analysis and immunoblotting of fibre‐type markers, including MyHC‐I, MyHC‐IIA and MyHC‐IIB. In vivo efficacy was evaluated in a dexamethasone‐induced and a sciatic nerve denervation‐induced rat models following oral administration of Med. Muscle histology, molecular signalling and functional performance were analysed. All immunoblots were analysed by densitometry.
Results
Med activated AdipoR1 and AdipoR2 with EC 50 values of 160 and 302 pM, respectively, and stimulated canonical adiponectin signalling pathways, including AMPK, AKT and p38 MAPK. It significantly induced expression of typical adiponectin targets, PGC‐1α, PPARα, Glut4 and UCP3 ( p < 0.0001). AdipoR1 knockdown completely abolished Med‐mediated signalling, whereas AdipoR2 depletion caused partial attenuation. Med enhanced myogenic differentiation, evidenced by increasing myotube formation and expression of MyoD, myogenin and MyHC. It protected myotubes against dexamethasone‐, cytokine‐ and nutrient deprivation‐induced atrophy by preserving CSA and Feret's diameter ( p < 0.0001), which was accompanied by suppression of Atrogin‐1 and MuRF1, and increased MyoD and myogenin expression ( p < 0.05). Med also enhanced oxidative capacity by increasing fatty acid oxidation and Med‐treated cells showed elevated oxidative fibre markers. Oral administration of Med significantly attenuated muscle atrophy in both rat models, evidenced by improved muscle morphology, suppressed atrogenes, enhanced myogenic markers and increased muscle adiponectin expression and corresponding downstream signalling. Med markedly improved muscle function, including grip strength ( p < 0.0001), wire hanging ( p < 0.01) and rotarod performance ( p < 0.01) and toe‐spread ability of denervated limbs ( p < 0.01).
Conclusion
These findings identify Med as a potent small‐molecule orally bioavailable AdipoR agonist and provide proof‐of‐concept for AdipoR agonists as potential therapeutics for sarcopenia and muscle wasting disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
- Academy of Scientific and Innovative research (AcSIR), Ghaziabad, India.
- Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
- Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
- Laboratory Animal Facility, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
ORCID-Profile: Shubhrajyoti Das, Pallavi Awasthi, Md Rameez Moin, Shyamal Pal, Anushka Talukdar, Akhilesh Kumar, Nikhil Nikolas, Shruti Suhas Varode, Shamima Khatoon, Nabanita Das, Sourav Chattopadhyay, Madhav Nilkanth Mugale, Rajdeep Guha, Sabyasachi Sanyal, Atul Goel
Förderung
- Council of Scientific and Industrial Research, India
- Blockchain for Impact-BIOME
Zitieren
APA
Das, S., Awasthi, P., Moin, M. R., Pal, S., Talukdar, A., Kumar, A., Nikolas, N., Varode, S. S., Khatoon, S., Das, N., Chattopadhyay, S., Mugale, M. N., Guha, R., Sanyal, S., & Goel, A. (2026). A Novel Small‐Molecule Dual Adiponectin Receptor 1/2 Agonist Induces Myogenesis and Ameliorates Skeletal Muscle Atrophy. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70364
Vancouver
Das S, Awasthi P, Moin MR, Pal S, Talukdar A, Kumar A, et al. A Novel Small‐Molecule Dual Adiponectin Receptor 1/2 Agonist Induces Myogenesis and Ameliorates Skeletal Muscle Atrophy. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70364
BibTeX
@article{Das2026,
author = {Das, Shubhrajyoti and Awasthi, Pallavi and Moin, Md Rameez and Pal, Shyamal and Talukdar, Anushka and Kumar, Akhilesh and Nikolas, Nikhil and Varode, Shruti Suhas and Khatoon, Shamima and Das, Nabanita and Chattopadhyay, Sourav and Mugale, Madhav Nilkanth and Guha, Rajdeep and Sanyal, Sabyasachi and Goel, Atul},
title = {A Novel Small‐Molecule Dual Adiponectin Receptor 1/2 Agonist Induces Myogenesis and Ameliorates Skeletal Muscle Atrophy},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
doi = {10.1002/jcsm.70364}
}
EUVIMED